ROLE OF CALCIUM-ANTAGONISTS IN PROGRESSION OF ARTERIOSCLEROSIS - EVIDENCE FROM ANIMAL-EXPERIMENTS AND CLINICAL-EXPERIENCE .1. PREVENTIVE EFFECTS OF CALCIUM-ANTAGONISTS IN ANIMAL-EXPERIMENTS

被引:0
作者
FREY, M
JUST, H
机构
关键词
CALCIUM ANTAGONISTS; HUMAN ARTERIOSCLEROSIS; EXPERIMENTAL ARTERIOSCLEROSIS; VASOPROTECTION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The quantitative predominance of free and total cholesterol over the amount of mural calcium is a most significant criterion of healthy human coronary arteries during the whole life span (0 - 90 years). However, this normal ratio increasingly changes as soon as arteriosclerotic alterations of the coronary walls set in. Accordingly, the mural calcium content steadily rises from fatty streaks over severe arteriosclerosis and, lastly, seems to reach a climax in plaques which caused lethal coronary infarction. Furthermore, the severe arteriosclerosis of human art. dorsalis pedis with gangrene (and amputation) is characterized by a tremendous calcium incorporation and absence of any mural cholesterol changes. Only in rare cases of human basilary plaques was a dangerous cholesterol incorporation in brain arterial wall found without significant elevation of serum cholesterol levels. The presented data indicate the existence of two different types of arteriosclerosis in one and the same patient and two basically different types of experimental coronary plaques according to their chemical composition, microscopic aspect and responsiveness to calcium antagonists: 1) the calcium type, developing in vitamin-DS-treated rats, and 2) the cholesterol type, represented by fatty coronary atheromata of cholesterol-fed rabbits. Coronary atheromata of cholesterol-fed New Zealand rabbits may be suitable models for coronary heart disease in rare cases of human familiar hypercholesterolemia. The formation of conventional human coronary artery plaques, however, essentially requires a progressive uptake of calcium, thereby representing a calcium dominated type of arteriosclerosis. Calcium antagonists specifically inhibit progredient mural calcium uptake in all experimental models of arteriosclerosis tested so far. However, neither in atheromatous arteries nor in afflicted organs (myocardium, liver, kidneys) of cholesterol-fed rabbits were we able to find any significant prevention of cholesterol accumulation by calcium antagonist.
引用
收藏
页码:161 / 176
页数:16
相关论文
共 60 条
[1]  
ANITSCHKOW N, 1913, ZENTRALBL ALLGEMEINE, V14, P1
[2]  
BETZ E, 1988, ANN NY ACAD SCI, V522, P399
[3]   MECHANISM OF PROTECTION FROM ATHEROSCLEROSIS BY VERAPAMIL IN THE CHOLESTEROL-FED RABBIT [J].
BLUMLEIN, SL ;
SIEVERS, R ;
KIDD, P ;
PARMLEY, WW .
AMERICAN JOURNAL OF CARDIOLOGY, 1984, 54 (07) :884-889
[4]   The chemical age change of vessels. [J].
Burger, M .
ZEITSCHRIFT FUR DIE GESAMTE NEUROLOGIE UND PSYCHIATRIE, 1939, 167 :273-280
[5]  
CATAPANO AL, 1988, ANN NY ACAD SCI, V522, P519
[6]  
EISENSTEIN R, 1964, ARCH PATHOL, V77, P27
[8]   THE ROLE OF CALCIUM IN THE PATHOGENESIS OF EXPERIMENTAL ARTERIOSCLEROSIS [J].
FLECKENSTEIN, A ;
FREY, M ;
ZORN, J ;
FLECKENSTEINGRUN, G .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1987, 8 (12) :496-501
[9]   EXCESSIVE MURAL CALCIUM OVERLOAD - A PREDOMINANT CAUSAL FACTOR IN THE DEVELOPMENT OF STENOSING CORONARY PLAQUES IN HUMANS [J].
FLECKENSTEIN, A ;
FREY, M ;
THIMM, F ;
FLECKENSTEINGRUN, G .
CARDIOVASCULAR DRUGS AND THERAPY, 1990, 4 :1005-1014
[10]   EXPERIMENTAL ANTIARTERIOSCLEROTIC EFFECTS OF CALCIUM-ANTAGONISTS [J].
FLECKENSTEIN, A ;
FLECKENSTEINGRUN, G ;
FREY, M ;
THIMM, F .
JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (02) :151-154